Carvedilol

Generic Name: Carvedilol

Brand Names: Coreg

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₆N_₂O_₄

CAS Number: 72956-09-3

Unique Ingredient Identifier: 0K47UL67F2

Background: Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension.

Carvedilol was granted FDA approval on 14 September 1995.

Indication: Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.

Associated Conditions: Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)

Clinical Trials

Carvedilol vs. Propranolol in Second Prophylaxis of Variceal Bleeding

Not Applicable

Not yet recruiting

Conditions: Cirrhosis, Liver
Varice Bleed
Portal Hypertension

Interventions: Drug: Carvedilol
Drug: Propranolol

First Posted Date: 2022-12-15

Last Posted Date: 2022-12-15

Lead Sponsor: West China Hospital

Target Recruit Count: 160

Registration Number: NCT05651789

Clinical Study Evaluating the Gastroprotective Effect of Carvedilol in Patients With Ischemic Heart Disease on Aspirin Therapy

Not Applicable

Not yet recruiting

Conditions: Gastro-Intestinal Disorder
Aspirin Induced Esophageal Ulcer
IHD

Interventions: Drug: Carvedilol

First Posted Date: 2022-09-23

Last Posted Date: 2022-09-23

Lead Sponsor: Tanta University

Target Recruit Count: 66

Registration Number: NCT05553717

Carvedilol in HF With Preserved EF

Phase 4

Recruiting

Conditions: Heart Failure With Preserved Ejection Fraction
Beta Blocker
Myocardial Strain

Interventions: Drug: Carvedilol
Drug: Placebo

First Posted Date: 2022-09-23

Last Posted Date: 2023-11-08

Lead Sponsor: Seoul National University Bundang Hospital

Target Recruit Count: 100

Registration Number: NCT05553314

Locations: 🇰🇷
Samsung Medical Center, Seoul, Il-won, Korea, Republic of
🇰🇷
Wonju Severance Christian Hospital, Wonju, Korea, Republic of

Acute Hemodynamic Response to Carvedilol in Predicting Survival in Acute on Chronic Liver Failure Patients - A Pilot Study.

Not Applicable

Recruiting

Conditions: Acute on Chronic Liver Failure

Interventions: Drug: Carvedilol 12.5 MG

First Posted Date: 2022-01-06

Last Posted Date: 2022-01-11

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 50

Registration Number: NCT05180292

Locations: 🇮🇳
Institute of Liver & Biliary Sciences, New Delhi, Delhi, India

Effect of Carvedilol Rapid Up-Titration in Patients With Heart Failure With Reduced Ejection Fraction

Phase 4

Conditions: Heart Failure With Reduced Ejection Fraction HFrEF

Interventions: Drug: Carvedilol

First Posted Date: 2022-01-05

Last Posted Date: 2022-01-05

Lead Sponsor: Universitas Sebelas Maret

Target Recruit Count: 26

Registration Number: NCT05179070

Locations: 🇮🇩
Universitas Sebelas Maret Hospital, Sukoharjo, Central Of Java, Indonesia

Efficacy and Safety of Carvedilol in Cirrhosis Patients With Uncomplicated Ascites Without High Risk Esophageal Varices

Not Applicable

Completed

Conditions: Liver Cirrhosis

Interventions: Drug: Carvedilol
Drug: Standard Medical Treatment

First Posted Date: 2021-09-27

Last Posted Date: 2025-03-20

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 104

Registration Number: NCT05057572

Locations: 🇮🇳
Institute of Liver & Biliary Sciences, New Delhi, Delhi, India

Extension Study of Carvedilol RCT Study

Not Applicable

Recruiting

Conditions: Liver Cirrhosis
Portal Hypertension

Interventions: Drug: Carvedilol 12.5 MG

First Posted Date: 2021-08-25

Last Posted Date: 2021-08-25

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 240

Registration Number: NCT05021406

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
Beijing Ditan Hospital, Capital Medical University, Beijing, Beijing, China

and more 11 locations